Puretech announces publication of research from collaborators demonstrating puretech's glyph™ platform enhances oral absorption of buprenorphine (a clinically-validated opioid replacement therapy)

Boston--(business wire)--puretech announced the publication of preclinical poc demonstrating that the glyph platform can enhance the oral bioavailability of buprenorphine

PRTC Ratings Summary

PRTC Quant Ranking